MX2009002906A - Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia. - Google Patents

Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.

Info

Publication number
MX2009002906A
MX2009002906A MX2009002906A MX2009002906A MX2009002906A MX 2009002906 A MX2009002906 A MX 2009002906A MX 2009002906 A MX2009002906 A MX 2009002906A MX 2009002906 A MX2009002906 A MX 2009002906A MX 2009002906 A MX2009002906 A MX 2009002906A
Authority
MX
Mexico
Prior art keywords
insulin resistance
metabolic disorders
disorders related
haperglycemia
treatment
Prior art date
Application number
MX2009002906A
Other languages
English (en)
Spanish (es)
Inventor
Nabajyoti Deka
Swapnil Ramesh Bajare
Sivaramakrishnan Hariharan
Rosalind Adaikalasamy Marita
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of MX2009002906A publication Critical patent/MX2009002906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MX2009002906A 2006-09-21 2007-09-20 Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia. MX2009002906A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84619406P 2006-09-21 2006-09-21
US87567206P 2006-12-18 2006-12-18
PCT/IB2007/053811 WO2008035305A2 (en) 2006-09-21 2007-09-20 Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia

Publications (1)

Publication Number Publication Date
MX2009002906A true MX2009002906A (es) 2009-06-30

Family

ID=39048032

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009002905A MX2009002905A (es) 2006-09-21 2007-09-20 Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos.
MX2009002906A MX2009002906A (es) 2006-09-21 2007-09-20 Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009002905A MX2009002905A (es) 2006-09-21 2007-09-20 Derivados de 3-amino-piridina para el tratamiento de trastornos metabolicos.

Country Status (19)

Country Link
US (5) US8269010B2 (enExample)
EP (2) EP2094687A1 (enExample)
JP (2) JP5331953B2 (enExample)
KR (2) KR20090074775A (enExample)
AR (2) AR062940A1 (enExample)
AT (1) ATE496890T1 (enExample)
AU (2) AU2007298540B2 (enExample)
BR (2) BRPI0717106A2 (enExample)
CA (2) CA2663901A1 (enExample)
DE (1) DE602007012299D1 (enExample)
DK (1) DK2094663T3 (enExample)
IL (2) IL197695A0 (enExample)
MX (2) MX2009002905A (enExample)
NZ (2) NZ576197A (enExample)
PL (1) PL2094663T3 (enExample)
PT (1) PT2094663E (enExample)
RU (2) RU2460729C2 (enExample)
TW (2) TW200817364A (enExample)
WO (2) WO2008035305A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013117963A1 (en) 2012-02-09 2013-08-15 Piramal Enterprises Limited Stable oral tablet dosage form of an antidiabetic compound
WO2014207508A1 (en) * 2013-06-27 2014-12-31 Piramal Enterprises Limited Pyridyl compound suitable for the treatment of metabolic disorders
TR201907981T4 (tr) 2013-06-27 2019-06-21 Pfizer Heteroaromatik bileşikler ve bunların dopamin d1 ligandları olarak kullanımı.
EA028614B1 (ru) * 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084085A (en) * 1986-08-20 1992-01-28 Fmc Corporation Herbicidal aryloxyphenyltriazolinones and related compounds
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6583157B2 (en) * 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
AU782404B2 (en) * 1999-04-28 2005-07-28 Sanofi-Aventis Deutschland Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
HK1043369B (en) * 1999-06-30 2014-06-13 日本烟草产业株式会社 Compounds for the modulation of ppar-gamma activity
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
HUP0301482A3 (en) * 2000-06-28 2005-12-28 Japan Tobacco Inc Quinolinnyl and benzothiazolyl ppar-gamma modulators pharmaceutical compositions containing them and their use
CA2526204A1 (en) * 2003-06-12 2004-12-23 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US8188277B2 (en) * 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
KR100874313B1 (ko) * 2004-10-04 2008-12-18 에프. 호프만-라 로슈 아게 당뇨병을 치료하기 위한 11-베타 억제제로서의 알킬-피리딘

Also Published As

Publication number Publication date
AU2007298539A1 (en) 2008-03-27
NZ576197A (en) 2011-12-22
RU2460729C2 (ru) 2012-09-10
US20090247574A1 (en) 2009-10-01
IL197694A0 (en) 2009-12-24
RU2448093C2 (ru) 2012-04-20
WO2008035305A3 (en) 2008-06-12
AR062940A1 (es) 2008-12-17
US8030324B2 (en) 2011-10-04
DE602007012299D1 (de) 2011-03-10
BRPI0718510A2 (pt) 2013-11-19
KR20090074775A (ko) 2009-07-07
NZ576196A (en) 2011-12-22
AU2007298540A1 (en) 2008-03-27
ATE496890T1 (de) 2011-02-15
TW200820970A (en) 2008-05-16
JP2010504321A (ja) 2010-02-12
RU2009114545A (ru) 2010-10-27
AR062941A1 (es) 2008-12-17
CA2663901A1 (en) 2008-03-27
MX2009002905A (es) 2009-06-19
KR20090075827A (ko) 2009-07-09
US8349862B2 (en) 2013-01-08
US20100022554A1 (en) 2010-01-28
WO2008035306A1 (en) 2008-03-27
AU2007298540B2 (en) 2013-02-21
DK2094663T3 (da) 2011-04-26
EP2094687A1 (en) 2009-09-02
BRPI0717106A2 (pt) 2013-10-08
AU2007298539B2 (en) 2013-05-02
PT2094663E (pt) 2011-04-19
US20120309786A1 (en) 2012-12-06
RU2009114544A (ru) 2010-10-27
US20130040988A1 (en) 2013-02-14
EP2094663B1 (en) 2011-01-26
CA2663943A1 (en) 2008-03-27
JP5331953B2 (ja) 2013-10-30
EP2094663A2 (en) 2009-09-02
US8269010B2 (en) 2012-09-18
IL197695A0 (en) 2009-12-24
JP2010504322A (ja) 2010-02-12
WO2008035305A2 (en) 2008-03-27
US20110312970A1 (en) 2011-12-22
PL2094663T3 (pl) 2011-07-29
WO2008035305A8 (en) 2009-03-12
TW200817364A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
WO2008055870A8 (en) Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2008034859A8 (en) Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200801029A (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
SG155961A1 (en) Pyrazoles as 11-beta-hsd-1
MX2010009922A (es) Activadores de piridazinona glucocinasa.
IL173203A0 (en) Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
PH12015500860A1 (en) 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
TW200806311A (en) Neuropeptide-2 receptor-agonists
IN2012DN03042A (enExample)
MX2009013501A (es) Compuestos piperidinicos y sus usos.
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status